SOAT1 and sarcoidosis: Although very speculative, the association between NRLP3 activation and disease course, irrespective of mTORC1 and STAT activation, could suggest that inhibiting the inflammasome pathway might be more effective than the use of mTORC1- and STAT inhibitors in the treatment of sarcoidosis.